Evidence map›Paper›PMID 40584454›Full record

ArticleGenetics in medicine open2025

Successes of an innovative population-based carrier screening program for 4 prevalent recessive hereditary diseases in a population with a founder effect in Quebec, Canada.

Carol-Ann Fortin, Mélanie Côté-Richer, Karine Truchon, Josianne Leblanc, Annabelle Pratte, Jessica Tardif, Marie-Jacqueline Thomas, Josée Villeneuve, Jean Mathieu, Doria Grimard and 5 more

Abstract read
In one paragraph

Article in Genetics in medicine open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. HeterozygousFrontiers in physiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Carol-Ann FortinFaculty of Medicine, Université de Montréal, Montreal, QC, Canada.
Mélanie Côté-RicherDepartment of Laboratory Medicine, Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Saguenay-Lac-Saint-Jean (SLSJ), Hôpital universitaire de Chicoutimi, QC, Canada.
Karine TruchonDepartment of Laboratory Medicine, Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Saguenay-Lac-Saint-Jean (SLSJ), Hôpital universitaire de Chicoutimi, QC, Canada.
Josianne LeblancDepartment of Laboratory Medicine, Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Saguenay-Lac-Saint-Jean (SLSJ), Hôpital universitaire de Chicoutimi, QC, Canada.
Annabelle PratteDepartment of Laboratory Medicine, Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Saguenay-Lac-Saint-Jean (SLSJ), Hôpital universitaire de Chicoutimi, QC, Canada.
Jessica TardifDepartment of Laboratory Medicine, Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Saguenay-Lac-Saint-Jean (SLSJ), Hôpital universitaire de Chicoutimi, QC, Canada.
Marie-Jacqueline ThomasDepartment of Laboratory Medicine, Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Saguenay-Lac-Saint-Jean (SLSJ), Hôpital universitaire de Chicoutimi, QC, Canada.
Josée VilleneuveDirection des Soins Infirmiers, de l'Enseignement, de la Recherche et de l'Innovation, CIUSSS du SLSJ, Chicoutimi, QC, Canada.
Jean MathieuNeuromuscular diseases interdisciplinary research group (GRIMN), Saguenay-Lac-St-Jean Integrated University Health and Social Services Center, Saguenay, QC, Canada.
Doria GrimardDepartment of Laboratory Medicine, Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Saguenay-Lac-Saint-Jean (SLSJ), Hôpital universitaire de Chicoutimi, QC, Canada.
Mathieu DesmeulesClinique des maladies métaboliques, CIUSSS du SLSJ, Hôpital universitaire de Chicoutimi, QC, Canada.
Claudia MoreauDépartement des Sciences Fondamentales, Université du Québec à Chicoutimi, Saguenay, QC, Canada.
Simon GirardDépartement des Sciences Fondamentales, Université du Québec à Chicoutimi, Saguenay, QC, Canada.
Tania Cruz-MarinoDepartment of Laboratory Medicine, Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Saguenay-Lac-Saint-Jean (SLSJ), Hôpital universitaire de Chicoutimi, QC, Canada.
Luigi BouchardDepartment of Laboratory Medicine, Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Saguenay-Lac-Saint-Jean (SLSJ), Hôpital universitaire de Chicoutimi, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The Saguenay-Lac-Saint-Jean, Haute-Côte-Nord, and Charlevoix regions in Canada have a high prevalence of 4 autosomal recessive diseases with high morbidity and/or reduced life expectancy. As a result, a carrier screening program (CSP) was developed in 2010 and has been ongoing since. The program's purpose is to provide information and carrier screening for individuals having a higher probability to have an affected child to allow for informed decision making regarding reproductive choices. This publication provides an overview of the CSP, shares its results, and discusses the growing needs for expanding genetic testing and counseling. Methods: In 2018, the CSP transitioned from a regional to a provincially available program, supported by an innovative home self-sampling kit that can be requested online and returned by mail for analysis. For the purpose of this study, CSP data from 2010 to 2022 were extracted and analyzed. Results: The CSP has shown high acceptability. In total, 20,604 participants have been tested, identifying 3578 carriers of at least 1 condition who received genetic counseling. Carrier couples for the same condition ( Conclusion: The relatively inexpensive method could be applied to other populations with a high prevalence of certain autosomal recessive diseases. Given the program's results, we must consider adding the screening of other prevalent recessive conditions to the CSP.

Indexed as

Autosomal recessiveCarrier screeningFounder effectGenetic counselingSaguenay-Lac-Saint-Jean

Identifiers

PMID40584454
PMCPMC12206014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.